Ponatinib 30 mg QD
AP24534-15-303
Phase 3 small_molecule terminated
Quick answer
Ponatinib 30 mg QD for Chronic Phase Chronic Myeloid Leukemia is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Chronic Phase Chronic Myeloid Leukemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated